Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from W.G.E. Direcks and colleagues has provided new data on breast cancer
September 4th, 2008
"Increased 2'-deoxy-2'-[F-18]fluoro-D-glucose (FDG) uptake is the most commonly used marker for positron emission tomography in oncology. However, a proliferation tracer such as 3'-deoxy-3'-[F-18]fluorothymidine (FLT) might be more specific for cancer. 3'-deoxy-3'-[F-18] fluorothymidine uptake is dependent on thymidine kinase 1 (TK) activity, but the effects of chemotherapeutic agents are unknown," investigators in Netherlands report. "The aim of this study was to characterise FDG and FLT uptake mechanisms in vitro before and after exposure to chemotherapeutic agents. The effects of 5-fluorouracil (5-FU), doxorubicin and paclitaxel on FDG and FLT uptake were measured in...
Source: Women's Health Weekly (2008-09-04)
|
